Brainsway Stock Performance
| BRSYF Stock | USD 3.15 0.00 0.00% |
On a scale of 0 to 100, BrainsWay holds a performance score of 9. The firm shows a Beta (market volatility) of -0.0521, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BrainsWay are expected to decrease at a much lower rate. During the bear market, BrainsWay is likely to outperform the market. Please check BrainsWay's risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis , to make a quick decision on whether BrainsWay's price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in BrainsWay are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, BrainsWay reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 17 M | |
| Total Cashflows From Investing Activities | -42.2 M |
BrainsWay |
BrainsWay Relative Risk vs. Return Landscape
If you would invest 210.00 in BrainsWay on August 30, 2024 and sell it today you would earn a total of 105.00 from holding BrainsWay or generate 50.0% return on investment over 90 days. BrainsWay is currently producing 0.7937% returns and takes up 6.2994% volatility of returns over 90 trading days. Put another way, 56% of traded pink sheets are less volatile than BrainsWay, and 85% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BrainsWay Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BrainsWay's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BrainsWay, and traders can use it to determine the average amount a BrainsWay's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BRSYF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.3 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.79 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average BrainsWay is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BrainsWay by adding it to a well-diversified portfolio.
BrainsWay Fundamentals Growth
BrainsWay Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BrainsWay, and BrainsWay fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BrainsWay Pink Sheet performance.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | (24.98 M) | |||
| Shares Outstanding | 33.08 M | |||
| Price To Earning | (23.91) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 1.11 X | |||
| Revenue | 29.66 M | |||
| EBITDA | (3.31 M) | |||
| Cash And Equivalents | 52.45 M | |||
| Cash Per Share | 1.50 X | |||
| Total Debt | 754 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | 884 K | |||
| Earnings Per Share | (0.22) X | |||
| Total Asset | 75.73 M | |||
| Retained Earnings | (47 M) | |||
| Current Asset | 14 M | |||
| Current Liabilities | 4 M | |||
About BrainsWay Performance
By analyzing BrainsWay's fundamental ratios, stakeholders can gain valuable insights into BrainsWay's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BrainsWay has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BrainsWay has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people.Things to note about BrainsWay performance evaluation
Checking the ongoing alerts about BrainsWay for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BrainsWay help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BrainsWay is way too risky over 90 days horizon | |
| BrainsWay appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 29.66 M. Net Loss for the year was (6.46 M) with profit before overhead, payroll, taxes, and interest of 24.35 M. | |
| About 20.0% of the company shares are held by company insiders |
- Analyzing BrainsWay's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BrainsWay's stock is overvalued or undervalued compared to its peers.
- Examining BrainsWay's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BrainsWay's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BrainsWay's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BrainsWay's pink sheet. These opinions can provide insight into BrainsWay's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BrainsWay Pink Sheet analysis
When running BrainsWay's price analysis, check to measure BrainsWay's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrainsWay is operating at the current time. Most of BrainsWay's value examination focuses on studying past and present price action to predict the probability of BrainsWay's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrainsWay's price. Additionally, you may evaluate how the addition of BrainsWay to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |